The first U.S. surgical usage of Aurora Spine Corporation’s AmnioPUR took place this October in a lumbar spine procedure. AmnioPUR is a multipurpose, chorion free, cryopreserved allograft derived from the amniotic membrane. “The clinical benefit of amnion is well documented; we just made it easier to use by providing AmnioPUR in a liquid form, ” said Brent W. Johnston, CCO of Aurora Spine.
According to the firm’s news release, AmnioPUR provides an anti-microbial environment with anti-inflammatory characteristics and anti-adhesion/anti-fibrotic capabilities and provides a structural matrix for use in filling bone voids and soft tissue.
“The launch of AmnioPUR is a major milestone for Aurora Spine, as we now offer surgeons a comprehensive liquid allograft solution from a provider they trust, ” said Trent J. Northcutt, Aurora president and CEO. “Surgeons know Aurora provides modern technologies for today’s patients ailing from spinal complications.”
Aurora Spine describes itself as being an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
